摘要
根治性切除是延长胰腺癌病人生存时间的有效手段,但约40%的病人在初诊时即为局部进展期胰腺癌而失去手术机会。通过制定个体化的新辅助治疗方案,有望使局部进展期胰腺癌降期,从而获得根治性切除的机会。目前,新辅助化疗后序贯放化疗是局部进展期胰腺癌最常见用的新辅助治疗方案,但具体的化疗药物并不统一,吉西他滨联合纳米紫杉醇以及FOLFIRINOX有望成为最佳化疗方案。
Radical resection is the effective means to prolong survival time of patients with pancreatic carcinoma. However, 40% of the patients are diagnosed with locally advanced pancreatic carcinoma in the first clinic. Individualized neoadjuvant treatment is expected to bring the stage-down of locally advanced pancreatic carcinoma, in order to gain the chance of radical excision. But the specific treatment is still controversial. Neoadjuvant chemotherapy followed by sequential chemoradiotherapy is the most common strategy in the neoadjuvant therapy. Gemcitabine plus nab-Paclitaxel and FOLFIRINOX are expected to be the best chemotherapy regimens.
出处
《中国实用外科杂志》
CSCD
北大核心
2017年第7期744-748,共5页
Chinese Journal of Practical Surgery
关键词
局部进展期胰腺癌
新辅助治疗
locally advanced pancreatic carcinoma
neoadjuvant therapy
